6.15

4.80% -0.31

After Hours: 6.37 0.22 +3.58%

Mind Medicine Inc (MNMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Mind Medicine Inc stock is traded at $6.15, with a volume of 945.89K. It is down -4.80% in the last 24 hours and up +8.27% over the past month. Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Previous Close:

$6.46

Open:

$6.46

24h Volume:

945.89K

Relative Volume:

0.55

Market Cap:

$523.57M

Revenue:

$11.40B

Net Income/Loss:

$-95.73M

P/E Ratio:

-2.5102

EPS:

-2.45

Net Cash Flow:

$-64.37M

1W Performance:

-11.26%

1M Performance:

+8.27%

6M Performance:

-27.56%

1Y Performance:

-32.57%

1-Day Range:

$6.03

$6.5253

1-Week Range:

$6.03

$6.9096

52-Week Range:

$4.70

$10.44

Mind Medicine Inc Stock (MNMD) Company Profile

Name

Mind Medicine Inc

Sector

Healthcare (1174)

Industry

Biotechnology (676)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

MNMD's Discussions on Twitter

Compare MNMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNMD Mind Medicine Inc	6.15	523.57M	11.40B	-95.73M	-64.37M	-2.45
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Mind Medicine Inc Stock (MNMD) Latest News

11:11 AM

Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance

11:11 AM

07:34 AM

Mind Medicine (MNMD) Rating and Price Target Maintained by Chardan Capital | MNMD Stock News - GuruFocus

07:34 AM

04:52 AM

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com

04:52 AM

03:11 AM